Ted Cruz's regulatory outsourcing plan for the FDA stirs controversy

Ted Cruz's plan to essentially outsource the drug approval process to other countries through a new reciprocal approval approach has been stirring a lot of discussion online. Vox starts with a largely upbeat tone on the prospect of faster approvals for new drugs, then turns to some key criticisms. "This would completely marginalize the FDA," said Aaron Kesselheim, a professor of medicine at Harvard Medical School. "It would allow the decision-making in other countries to have full power over the market in the United States." It would also largely eliminate the FDA's final word on approvals, giving Congress the right to override any of its decisions by a majority vote. Story

Suggested Articles

Outgoing BIO Chair John Maraganore and his successor, Jeremy Levin, reflected on drug pricing, its drivers and its place in the innovation ecosystem.

The study is assessing the effect of the oral AXL inhibitor when given to elderly AML patients in combination with low-intensity chemotherapy.

The proportion of patients who had a greater than 1 g/dL increase in hemoglobin is down on GBT’s prior update but still superior to placebo.